The hypocholesterolemic effect of an antacid containing aluminum hydroxide

The American Journal of Medicine

Volumn 91, Issue 6, 1991, Pages 597-604

  Sperber, Ami D ^a   Henkin, Yaakov ^a   Zuili, Irene ^a   Bearman, Jacob E ^b   Shany, Shraga ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM HYDROXIDE; PLACEBO; SIMETHICONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ALUMINUM; ALUMINUM HYDROXIDE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA, FAMILIAL; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0026349440     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(91)90212-G     Document Type: Article

References (35)

1. Binding properties in vitro of antacids for conjugated bile acids
2. Comparison of antacids on the binding of bile salts
3. Antacids and bile salts
4. The bile acid binding properties of antacids in vivo
5. The effect of an antacid containing aluminum hydroxide on plasma cholesterol and lipoproteins
6. Cholesterol determination in high-density lipoproteins separated by three different methods
7. Enzymatic determination of total serum cholesterol
8. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide
9. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
10. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study
11. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
12. The Lipid Research Clinics Coronary Primary Prevention Trial Results I Reduction in incidence of coronary heart disease
13. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
14. Report of the National Cholesterol Education Program Expert Panel on detection evaluation and treatment of high blood cholesterol in adults
15. The recognition and management of hyperlipidaemia in adults a policy statement of the European Atherosclerosis Society
16. Drugs used in the treatment of hyperlipoproteinemias
17. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolemia
18. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very-low-density lipoprotein triglycerides
19. Progress in understanding mechanisms of the serum cholesterol risk factor in atherosclerosis
20. Cholestyramine in type II hyperlipoproteinemia
21. The ability of antacids and cholestyramine to bind bile acids: effect of pH
22. The hepatobiliary axis and lipoprotein metabolism; effects of bile acid sequestrants and ileal bypass surgery
23. Laboratory and clinical evaluation of an adsorbent, modified aluminum hydroxide preparation in infected and noninfected diarrhoea
24. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes
25. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia
26. Complementarity of colestipol, niacin and lovastatin in treatment of severe familial hypercholesterolemia
27. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels
28. Mechanism of action of bile acid sequestrants and other lipidlowering drugs
29. New horizons in combination drug therapy for hypercholesterolemia
30. Effect of combined therapy with bezafibrate and cholestyramine on low-density-lipoprotein metabolism in type IIa hypercholesterolemia
31. Gastrointestinal absorption of aluminum from aluminum-containing antacids
32. Rapid fall of serum phosphorus secondary to antacid therapy
33. Urinary excretion of aluminium after ingestion of sucralfate and an aluminium-containing antacid in man